| Detailed information |
|---|
| CancerLivER ID | 2588 |
| Biomarker | NM23-H2,MCM7, PARP1, YWHAH, HSPB1, MSH2 |
| Biomarker Name/Symbol (given in Publication) | NM23-H2,MCM7, PARP1, YWHAH, HSPB1 and MSH2 |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Potential diagnostic marker for HVB-HCC; but not validated on independent datase |
| Experimental Condition | HCC v/s non-tumor |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in tumor |
| Level of significance | P<0.001 |
| Source | Tissue |
| PMID | 16703398 |
| Type of Biomarker | Diagnostic |
| Pathway | hepatocarcinogenesis |
| Cohort | 15 tumor and five non-tumorous liver samples from15 HCC patients who were sero-positive for hepatitis B surface antigen and seronegative for anti-hepatitis C virus antibody. |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | HCV-HCC vs Normal |
| Year of Publication | 2006 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |